Broad Pipeline of Investigational
Product Candidates
to Fight Cancer
Leading Multispecific Antibody
Technology Platforms
and Protein Engineering Expertise
Developing Breakthrough Biologics,
Life-Changing
Medicines
Fully-integrated, Antibody-based
Development Capabilities,
Including GMP Manufacturing
Focused on Developing
Innovative Medicines
for Patients with Unmet Needs
DEVELOPING BREAKTHROUGH BIOLOGICS,
LIFE-CHANGING
MEDICINES
Overview

We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Click on the link below for our latest corporate presentation.

Upcoming Events & Presentations

We participate in many investor and scientific conferences throughout the year and routinely make available related webcasts and presentations.

Clink on the link below for details on past and future events.

Latest News

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
Read More

MacroGenics to Participate in Upcoming Investor Conference
Read More

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close